Lisure Science (Suzhou) Co.,Ltd.(Lisure), founded in 2009 with a registered capital of 18.14433 million yuan, is a state high-tech enterprise situated in Suzhou Industrial Park (SIP). The company has set up a 20,000sqm industrial manufacturing base and a 3,000sqm application development technical center. It has 185 employees, 60 or 30% of the total are R&D staff, and over 85% of the total have the college education and above. Lisure is a professional provider of bio-medicine separation and purification technologies and products. It offers products and services for more than 800 pharmaceutical enterprises and R&D institutions in bio-medicine fields including monoclonal antibody, recombinant protein, vaccine and blood products. The company focuses on development and scale-up of separation and purification process, selection and optimization of separation media, customization of separation and purification equipment, design and implementation of separation and purification projects, and offers integrate plans for biomedicine customers. It also can offer automatic, intelligent and individualized plans for filtration, separation, chromatographic purification, online liquid preparation and other bio-medicine production processes. Lisure’s products and services cover the full process from drug discovery to lab batch, scale-up and mass production.
The company applied for 32 invention patents including 20 authorized ones, has 12 authorized practical new patents, 5 software copyrights, 3 registered trademarks, and 8 products honored Jiangsu Provincial High-tech Products. Lisure was honored SIP Leading Growth Enterprises in 2013 and state high-tech enterprises in 2017, achieved sales revenue of 72 million yuan in 2016 and 122 million yuan in 2017, up 70% year on year. It is expected to Lisure will realize a sales revenue of 180 million yuan and strive to achieve 200 million yuan in 2018.
In 2014, the new-type high efficiency separation and purification system industrialization project independently developed by the company was granted “protein bio-medicine and vaccine” development major project by National Development and Reform Commission, Ministry of Industry and Information Technology, National Health and Family Planning Commission and Ministry of Finance with project support fund amounting to 12 million yuan. It was the only industrialization development project for the support products of bio-medicine. In November 2017, Lisure won the provincial sci-tech achievement transformation support of Jiangsu Provincial Sci-tech Administration. The project R&D and Industrialization of Nanometer New Type Bio-medicine High Efficiency Separation and Purification System received the supportive fund of 6 million yuan. In 2017, the company’s Bio-medicine Separation and Purification Engineering Technical Center was unveiled upon the approval of Jiangsu Provincial Sci-tech Administration. In addition, Lisure plans to complete the stock system reform in 2018 and be listed on the Growth Enterprise Market in 2020.